Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug naderin may help patients fight infections during cancer and TB therapy

NCT ID NCT07671508

Disease control Sponsor: MIPO Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. Results showed that Naderin shortened the duration of low white blood cell counts by 4-5 days and reduced the number of infections, suggesting it may help patients better tolerate aggressive treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Naderin (sodium nucleinate)
What this could lead to
If it works, this could provide a supportive treatment to help patients better tolerate chemotherapy and other aggressive therapies by reducing infections and blood cell count drops.
What could go wrong
This is a small, completed Phase 2/3 trial with only 75 participants. Results may not apply to all patients, and the drug's safety and effectiveness need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

75 people

The number who actually took part.

Started

May 2013

Finished

Mar 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of malignant neoplasm, tuberculosis, or hepatitis C (confirmed by clinical, laboratory, and/or histopathological criteria) * Age between 18 and 50 years at the time of enrollment * Receiving standard basic therapy (chemotherapy, anti-tuberculosis therapy, or antiviral therapy) according to national clinical protocols * Signed informed consent to participate in the study * Willingness to comply with study procedures and follow-up visits * ECOG performance status ≤ 2 or equivalent Exclusion Criteria: * Severe concomitant diseases (e.g., decompensated cardiovascular, renal, or hepatic failure) that could interfere with study participation or outcome assessment * Known hypersensitivity or contraindications to Naderin (sodium nucleinate) or its components * Pregnancy or lactation * Participation in any other interventional clinical trial within 30 days prior to enrollment * Active or uncontrolled infections (other than the primary study condition) * Severe immunodeficiency (e.g., HIV/AIDS, advanced hematological malignancies) not related to the primary study condition * Mental or cognitive impairment that would preclude informed consent or compliance with study procedures * History of organ transplantation requiring immunosuppressive therapy * Any other condition that, in the investigator's opinion, would make the participant unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C (HCV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hepatitis C virus infection neoplasm neutropenia tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C (HCV) Malignant neoplasms Tuberculosis (TB)

More trials for these conditions

Other studies related to the condition(s) this trial covers.